(Approval lapsed) KLACIPED FORTE clarithromycin 250mg/5mL granules for oral suspension (Switzerland)
Section 19A approved medicine
(Approval lapsed) KLACIPED FORTE clarithromycin 250mg/5mL granules for oral suspension (Switzerland)
Section 19A approval holder
Link Medical Products Pty Ltd ABN 73 010 971 516
Phone
1800 181 060
Approved until
Status
Expired
Medicines in short supply/unavailable
KLACID clarithromycin 250mg/5mL powder for oral liquid bottle - ARTG 56729
Indication(s)
Klaciped Forte is indicated for the following infections caused by pathogens sensitive to clarithromycin:
Based on experience in adults with clarithromycin (Klacid), Klaciped/Klaciped Forte are probably also indicated in the following infections, which have not yet been sufficiently proven by controlled pediatric studies:
- Respiratory tract infections: such as acute and chronic bronchitis, bronchopneumonia, pneumonia, atypical pneumonia, pneumonia due to Legionella pn., unless the severity of the condition requires parenteral therapy (for determining susceptibility see "Warnings and Precautions" and "Pharmacodynamics").
- Infections in the ear, nose and throat area: such as sinusitis.
- Skin infections: For mild superficial infections such as erysipelas, furunculosis, limited wound infections, cellulitis (for determining sensitivity see "Warnings and precautionary measures" and "Pharmacodynamics").
Official recommendations on the appropriate use of antibiotics should be observed, particularly recommendations for use to prevent the increase in antibiotic resistance.
Images
